All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Naval Daver, MD

home / authors / naval-daver-md

Articles

Advertisement

The Future of Myelodysplastic Syndrome

The Future of Myelodysplastic Syndrome

September 22nd 2021

An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.


Emerging First-Line Treatments for High-Risk Myelodysplastic Syndrome

Emerging First-Line Treatments for High-Risk Myelodysplastic Syndrome

September 22nd 2021

Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.


Treating Patients with High-Risk Myelodysplastic Syndrome

Treating Patients with High-Risk Myelodysplastic Syndrome

September 22nd 2021

An expert details the treatment options for high-risk myelodysplastic syndrome.


Treatment Options for Low-Risk Myelodysplastic Syndrome

Treatment Options for Low-Risk Myelodysplastic Syndrome

September 22nd 2021

Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.


Diagnosis of Myelodysplastic Syndrome

Diagnosis of Myelodysplastic Syndrome

September 22nd 2021

A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.


An Overview of Myelodysplastic Syndrome

An Overview of Myelodysplastic Syndrome

September 22nd 2021

Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.

Advertisement

Discussing Rationale of Azacitidine Plus Maintenance Therapy in AML

Discussing Rationale of Azacitidine Plus Maintenance Therapy in AML

December 18th 2019

Naval Daver, MD, explains the rationale for the phase II QUAZAR trial, which assessed the efficacy and safety of azacitidine in patients with acute myeloid leukemia.


Agents Under Investigation in AML

Agents Under Investigation in AML

September 13th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses agents being investigated in acute myeloid leukemia (AML).

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.